MedPath

Nabilone

Generic Name
Nabilone
Brand Names
Cesamet
Drug Type
Small Molecule
Chemical Formula
C24H36O3
CAS Number
51022-71-0
Unique Ingredient Identifier
2N4O9L084N
Background

Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Nabilone or Dronabinol), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

In Canada, the United States, the United Kingdom and Mexico, nabilone is marketed as Cesamet. It was approved in 1985 by the United States FDA for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics. Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS.

Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers.

Indication

Nabilone is indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Nabilone can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents.

Associated Conditions
Refractory Chemotherapy-Induced Nausea and Vomiting (CINV)
Associated Therapies
-

Cannabinoid Medication for Adults With OCD

Phase 1
Completed
Conditions
Obsessive-Compulsive Disorder
Interventions
Drug: Nabilone
Behavioral: Exposure and Response Prevention Therapy
First Posted Date
2016-09-22
Last Posted Date
2020-08-06
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
16
Registration Number
NCT02911324
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients

Phase 2
Conditions
Cachexia
Non-Small Cell Lung Cancer
Anorexia
Weight Lose
Interventions
Drug: Placebo
Drug: Nabilone
First Posted Date
2016-06-16
Last Posted Date
2016-08-31
Lead Sponsor
Instituto Nacional de Cancerologia de Mexico
Target Recruit Count
78
Registration Number
NCT02802540
Locations
🇲🇽

Instituto Nacional de Cancerologia, Mexico City, Mexico

Safety and Efficacy of Nabilone in Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer Disease
Agitation
Weight Loss
Pain
Oxidative Stress
Interventions
Drug: Placebo
Drug: Nabilone
First Posted Date
2015-01-30
Last Posted Date
2020-06-25
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
38
Registration Number
NCT02351882
Locations
🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet

Phase 2
Completed
Conditions
Postoperative Nausea and Vomiting
Interventions
Drug: Placebo
Drug: Nabilone
First Posted Date
2014-04-16
Last Posted Date
2015-12-03
Lead Sponsor
Unity Health Toronto
Target Recruit Count
331
Registration Number
NCT02115529
Locations
🇨🇦

St Michael's Hospital, Toronto, Ontario, Canada

Nabilone for Cannabis Dependence: A Pilot Study

Phase 2
Completed
Conditions
Cannabis Dependence
Marijuana Dependence
Interventions
Drug: Placebo
Drug: Nabilone
First Posted Date
2011-05-04
Last Posted Date
2018-06-01
Lead Sponsor
Mclean Hospital
Target Recruit Count
84
Registration Number
NCT01347762
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

Nabilone for the Treatment of Phantom Limb Pain

Phase 2
Completed
Conditions
Phantom Limb Pain
Neuropathic Pain
First Posted Date
2008-06-18
Last Posted Date
2011-04-29
Lead Sponsor
University of Manitoba
Target Recruit Count
50
Registration Number
NCT00699634
Locations
🇨🇦

Rehabilitation Hospital, Winnipeg, Manitoba, Canada

Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis

Phase 4
Completed
Conditions
Neuropathic Pain
Multiple Sclerosis
Interventions
Other: placebo
Drug: nabilone
First Posted Date
2007-05-30
Last Posted Date
2012-07-27
Lead Sponsor
University of Manitoba
Target Recruit Count
50
Registration Number
NCT00480181
Locations
🇨🇦

Health Sciences Centre Multiple Sclerosis Clinic, Winnipeg, Manitoba, Canada

A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting

Phase 4
Terminated
Conditions
Nausea and Vomiting
First Posted Date
2007-01-05
Last Posted Date
2010-12-02
Lead Sponsor
Veeda Oncology
Target Recruit Count
16
Registration Number
NCT00418678
Locations
🇺🇸

Veeda Oncology, Columbus, Ohio, United States

Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients

Phase 2
Conditions
Pain
Insomnia
First Posted Date
2006-10-06
Last Posted Date
2006-10-06
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
16
Registration Number
NCT00384410
Locations
🇨🇦

University Health Network, Toronto, Ontario, Canada

Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia

Not Applicable
Completed
Conditions
Fibromyalgia
Sleep Initiation and Maintenance Disorders
First Posted Date
2006-09-27
Last Posted Date
2007-05-21
Lead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Target Recruit Count
32
Registration Number
NCT00381199
Locations
🇨🇦

McGill University Health Centre, Pain Centre, Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath